Profile data is unavailable for this security.
About the company
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
- Revenue in GBP (TTM)13.12m
- Net income in GBP7.58m
- Incorporated2003
- Employees16.00
- LocationBioventix PLC7 Romans Business Park, East StreetFARNHAM GU9 7SXUnited KingdomGBR
- Phone+44 125 272 8001
- Fax+44 125 272 8002
- Websitehttps://www.bioventix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fusion Antibodies PLC | 1.60m | -1.47m | 18.44m | 24.00 | -- | 23.09 | -- | 11.55 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Sareum Holdings Plc | 0.00 | -4.44m | 25.54m | 5.00 | -- | 10.92 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
| Arecor Therapeutics PLC | 5.06m | -8.10m | 27.37m | 37.00 | -- | 9.58 | -- | 5.41 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 32.07m | 41.00 | -- | 3.40 | -- | 6.91 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Poolbeg Pharma PLC | 0.00 | -5.71m | 32.77m | 10.00 | -- | 2.75 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -3.93m | 35.14m | 6.00 | -- | 103.74 | -- | -- | -0.0089 | -0.0089 | 0.00 | 0.0007 | 0.00 | -- | -- | 0.00 | -139.44 | -89.81 | -259.88 | -121.17 | -- | -- | -- | -9,895.75 | -- | -2.76 | 0.00 | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| hVIVO PLC | 51.28m | 5.28m | 58.40m | 301.00 | 11.05 | 1.34 | 6.52 | 1.14 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.81m | 58.58m | 16.00 | -- | -- | -- | -- | -2.21 | -2.21 | 0.00 | -0.1089 | 0.00 | -- | -- | 0.00 | -169.60 | -87.04 | -210.76 | -102.48 | -- | -- | -- | -- | -- | -2.14 | 1.33 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.91m | 62.96m | 25.00 | -- | -- | -- | -- | -0.2519 | -0.2519 | 0.00 | -0.135 | 0.00 | -- | -- | 0.00 | -119.80 | -227.46 | -304.25 | -1,738.54 | -- | -- | -- | -- | -- | -1.65 | 3.64 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| 4Basebio PLC | 1.78m | -14.41m | 87.79m | -- | -- | 4.61 | -- | 49.35 | -0.9923 | -0.9923 | 0.1226 | 1.23 | 0.0729 | 1.54 | 21.56 | -- | -59.05 | -36.81 | -64.81 | -40.98 | 61.55 | 69.88 | -809.95 | -1,160.83 | 11.15 | -95.30 | 0.4485 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Bioventix PLC | 13.12m | 7.58m | 90.13m | 16.00 | 11.96 | 7.80 | 11.74 | 6.87 | 1.44 | 1.44 | 2.49 | 2.21 | 0.9864 | 1.84 | 2.10 | 819,741.90 | 57.04 | 58.17 | 64.40 | 64.19 | 90.86 | 92.79 | 57.83 | 61.84 | 8.65 | -- | 0.00 | 105.34 | -3.61 | 4.92 | -6.33 | 1.04 | -43.71 | 11.26 |
| Scancell Holdings Plc | 4.71m | -5.51m | 145.29m | 60.00 | -- | -- | -- | 30.84 | -0.0053 | -0.0053 | 0.0047 | -0.0081 | 0.2946 | -- | 8.26 | 78,516.66 | -34.46 | -33.29 | -- | -44.23 | 94.95 | -- | -116.98 | -502.03 | -- | -- | 2.07 | -- | -- | -- | -109.46 | -- | 124.48 | -- |
Data as of Feb 16 2026. Currency figures normalised to Bioventix PLC's reporting currency: UK Pound GBX
55.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Liontrust Investment Partners LLPas of 24 Oct 2025 | 571.00k | 10.93% |
| Sanford DeLand Asset Management Ltd.as of 24 Oct 2025 | 498.00k | 9.53% |
| Gresham House Asset Management Ltd. (Investment Management)as of 03 Mar 2025 | 421.00k | 8.06% |
| Schroder Investment Management Ltd.as of 24 Oct 2025 | 285.00k | 5.46% |
| Investec Wealth & Investment Ltd.as of 24 Oct 2025 | 269.00k | 5.15% |
| Raymond James Wealth Management Ltd. (Investment Management)as of 24 Oct 2025 | 264.00k | 5.05% |
| Santander Asset Management UK Ltd.as of 03 Mar 2025 | 213.00k | 4.08% |
| Rathbones Investment Management Ltd.as of 24 Oct 2025 | 187.00k | 3.58% |
| Danske Bank A/S (Investment Management)as of 30 Nov 2025 | 99.91k | 1.91% |
| Hargreaves Lansdown Fund Managers Ltd.as of 03 Mar 2025 | 88.00k | 1.68% |
More ▼
Data from 31 Jul 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
